| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Neomorph | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $208.74M | Series B | 4/13/2026 | $114.04M | $340.23M | $1.32 | Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Qventus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.63M | Series D-1 | 1/13/2025 | $35.81M | $400.12M | $7.95 | KKR, Bessemer Venture Partners, Northwestern Medicine, HonorHealth, Allina Health | ||||
 | Syncromune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.01M | Series A-1 | 8/21/2025 | $99.85M | $254.93M | $3.43 | Wasatch Equity Partners | ||||
 | Timberlyne Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $9.88M | Series A | 1/9/2025 | $9.37M | $137.37M | $3.64 | Abingworth, Bain Capital Life Sciences, Venrock, Boyu Capital, Lilly Asia Ventures, Braidwell, 3H Health Investment | ||||
 | Two Chairs | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $92.39M | Series C | 4/16/2024 | $40M | $250.37M | $8.00 | Amplo, Fifth Down Capital | ||||
 | Unlearn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.17M | Series C | 2/8/2024 | $50M | $368.17M | $9.24 | Altimeter Capital Management, Radical Ventures, Mubadala Capital, Wittington Ventures, EPIC Ventures, Necessary Ventures, Insight Partners, 8VC, DCVC | ||||
 | Well | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $183.32M | Series B-2 | 11/19/2025 | $30M | $486.14M | $16.00 | Undisclosed Investors | ||||
 | Zephyr AI | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.71M | Series A | 3/13/2024 | $69.01M | $482.26M | $17.34 | Revolution Growth, Eli Lilly and Company, Jeff Skoll, EPIQ Capital Group | ||||
 | Alterome Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $231.07M | Series B | 4/3/2024 | $132M | $356.19M | $4.08 | Goldman Sachs Alternatives, Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, OrbiMed, Nextech Invest, Vida Ventures, Boxer Capital, Colt Ventures | ||||
 | Ampersand Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.61M | Series B | 3/19/2025 | $65M | $360.94M | $5.80 | Flagship Pioneering, Eli Lilly & Company | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | BlueWillow Biologics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $37.19M | Series C | 9/19/2022 | $5.9M | $34.12M | $0.09 | Undisclosed Investors | ||||
 | Casana | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $139.73M | Series B | 1/21/2022 | $30M | $323.86M | $12.77 | Morningside, Matrix Partners, General Catalyst, Outsiders Fund | ||||
 | Centrexion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $569.49M | Series D | 9/30/2019 | $90.34M | $327.06M | $1.80 | New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital | ||||
 | Clear Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.08M | Series D | 1/13/2025 | $30M | $395.17M | $2.80 | Counterpoint Global, Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, T. Rowe Price Associates | ||||
 | Cooler Heads | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $23.97M | Series A-3 | 7/10/2026 | $3.27M | $34.04M | $1.15 | Undisclosed Investors | ||||
 | Curative | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $8.79M | Series A-7 | 9/23/2020 | $2.86M | $37.8M | $0.04 | DCVC, Refactor Capital, Chris Anderson | ||||
 | DeepScribe | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $59.19M | Series B | 1/3/2024 | $24M | $134.68M | $3.45 | Undisclosed Investors | ||||
 | Delix Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $102.25M | Series B | 1/10/2022 | $30M | $243.78M | $3.45 | ARTIS Ventures, RA Capital Management, OMX Ventures, Apeiron, Bail Capital, Casa Verde Capital, Dolby Family Ventures, Negev Capital, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, PsyMed Ventures, R2, Re.Mind Capital, Saya Bio, Vertical Venture Partners, WPSS | ||||
 | Digital Diagnostics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $123.99M | Series B | 8/23/2022 | $76.39M | $286.24M | $9.45 | KKR, Cedar Pine, Kinderhook, 8VC, Optum Ventures, OSF Ventures, Gundersen Health System, Edward - Elmhurst Health Venture Capital, University of Iowa, Edge Ventures | ||||
 | Doceree | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $45.11M | Series B-2 | 9/27/2023 | $7.5M | $271.1M | $104.20 | Creaegis, Eight Roads Ventures, F-Prime Capital | ||||
 | Eko Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $327.66M | Series D | 6/5/2024 | $41M | $271.32M | $1.72 | ARTIS Ventures, Highland Capital Partners, NTTVC, Questa Capital | ||||
 | Evozyne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.19M | Series B | 9/27/2023 | $50M | $288.32M | $15.49 | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | ||||